Table 4 Results of CGH analysis, FISH, SSCP analysis, and immunohistochemistry in malignant PCC

From: Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas

Samples

Patients

Characteristics

CGH 17p

FISH p53

SSCP

IH

 1

1

F/47 sp/adr/u

 2

2

F/65 sp/adr/u

 3

3

F/70 sp/adr/u

 4

4

F/56 sp/adr/u

 5

 

meta

 6

5

F/30 sp/ea/u

 7

 

Meta intercost I

 8

 

Meta intercost II

 9

6

M/70 sp/adr/u

10

 

Meta LN

11

7

F/53 sp/ea/u

12

 

Meta

13

8

F/27 sp/adr/u

14

9

F/32 sp/adr/u

15

 

Meta LN I

16

 

Meta LN II

17

10

M/32 sp/ea/u

18

11

M/36 sp/adr/u

19

 

Meta LN

20

12

F/23 sp/adr/u

21

 

Meta bone

22

13

F/62 sp/adr/u

23

14

M/42 sp/adr/u

24

15

M/42 sp/adr/u

25

16

F/39 sp/adr/u

26

 

/49 meta LN

27

17

F/45 sp/adr/u

28

 

Meta LN

29

18

F/32 sp/adr/u

30

 

Meta liver

  1. In CGH analysis, represents ‘no gain or loss,’ • is ‘loss,’ and means ‘gain’ of chromosome 17. In FISH analysis, is ‘retention of heterozygosity,’ • means ‘loss of heterozygosity,’ and represents ‘gain’ of the p53 locus on chromosome 17. In SSCP, means no mutation. In immunohistochemistry, represents ‘no overexpression’ and • means p53 protein overexpression. In all four techniques, — means that these samples are not examined. M=male; F=female; sp=sporadic; m=men; n=neurofibromatosis; adr=adrenal; ea=extra-adrenal; u=unilateral; bi=bilateral; Meta=metastasis; LN=lymph node.